第一类SAM竞争性G9a抑制剂FLAV-27作为阿尔茨海默氏症疾病修饰疗法
Aina Bellver-Sanchis1, David Valle-Garcia2, Carla Barbaraci3
1Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain.
Molecular therapy : the journal of the American Society of Gene Therapy
|December 25, 2025
概括
一种新的药物,FLAV-27,有效地向阿尔茨海默病 (AD) 的表观遗传变化. 这种穿透大脑的疗法减少了AD的关键病理,并在临床前模型中改善了认知功能.
科学领域:
- 神经科学是一个神经科学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及复杂的病理生理学,包括表观遗传失调.
- 基因组甲基转移酶G9a在AD病变发生过程中发挥作用.
研究的目的:
- 发现和验证FLAV-27,一种用于阿尔茨海默病的新型选择性G9a抑制剂.
- 在AD模型中评估FLAV-27的治疗潜力和生物标志物对齐.
主要方法:
- 临床前验证FLAV-27,一种SAM竞争性G9a抑制剂.
- 在体外测定Aβ/p-tau聚合和神经复杂性.
- 在Caenorhabditis elegans和AD小鼠模型中的体内研究 (SAMP8,5xFAD).
- 针对表观遗传和生物标志物概况的多组学分析.
主要成果:
- FLAV-27显示出亚纳米级功效,高选择性和中枢神经系统生物可用性.
- 减少了粉样蛋白β和p-tau聚合,在体外恢复了神经复杂性.
- 改善了C. elegans的移动性,寿命和线粒体呼吸.
- 在AD小鼠模型中挽救记忆,社会行为和突触结构.
- 在血和大脑中正常化的AD生物标志物 (SMOC1,H3K9me2,p-Tau181).
结论:
- FLAV-27是阿尔茨海默病的第一级表观遗传疗法.
- 该药物具有疾病修饰潜力,并与转化生物标志物保持一致.
- FLAV-27代表了对AD的有前途的新疗法策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
01:24Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933